Challenge for a better combination with basic evidence
- 14 June 2008
- journal article
- review article
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 13 (3) , 212-219
Abstract
5-Fluorouracil (5-FU) has been the most widely accepted and studied chemotherapeutic agent, and many combination chemotherapeutic regimens have been reported. However, until recently, a standard regimen for metastatic gastric cancer had not been established. The combination of S-1 and cisplatin is a good candidate as a standard first-line regimen for metastatic gastric cancer. On the other hand, interest in biochemical modulation has become wide spread recently. The low level of dihydropyrimidine denhydrogenase (DPD), thymidylate synthase (TS) activities, and a high level of orotate phosphoribosyl-transferase (OPRT) activity enhance the antitumor effect of 5-FU and S-1. Docetaxel is one of the agents that modulate these enzyme expressions and activities. Moreover, the response rate of combination therapy of docetaxel and S-1 for metastatic gastric cancer was 56.3% and median survival time was 14.3 months in a phase II study, showing it to be a good candidate for a new standard regimen for gastric cancer. A phase III collaborative study, START (S-1 and Taxotere for advanced gastric cancer randomized phase III trial), is now under way in Japan and Korea.Keywords
This publication has 55 references indexed in Scilit:
- S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trialThe Lancet Oncology, 2008
- Capecitabine and Oxaliplatin for Advanced Esophagogastric CancerNew England Journal of Medicine, 2008
- Synergistic effects of docetaxel and S‐1 by modulating the expression of metabolic enzymes of 5‐fluorouracil in human gastric cancer cell linesInternational Journal of Cancer, 2006
- Simple combinations of 5‐FU pathway genes predict the outcome of metastatic gastric cancer patients treated by S‐1International Journal of Cancer, 2006
- Current status and future prospects of chemotherapy for metastatic gastric cancer: a reviewGastric Cancer, 2005
- Recent advances in multimodal treatment for gastric cancer: a reviewGastric Cancer, 2005
- Nuclear Factor-κB Activation Correlates with Better Prognosis and Akt Activation in Human Gastric CancerClinical Cancer Research, 2005
- Relationships between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase and cell proliferative activity and 5-fluorouracil sensitivity in colorectal carcinomaInternational Journal of Clinical Oncology, 2003
- Recent Advances in the Treatment of Gastric CancerDrugs, 2001
- Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M tegafur–0.4M gimestat–1M otastat potassium) in advanced gastric cancer patientsEuropean Journal of Cancer, 1998